"Cell Line, Tumor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cell line derived from cultured tumor cells.
| Descriptor ID |
D045744
|
| MeSH Number(s) |
A11.251.210.190 A11.251.860.180
|
| Concept/Terms |
Cell Line, Tumor- Cell Line, Tumor
- Cell Lines, Tumor
- Line, Tumor Cell
- Lines, Tumor Cell
- Tumor Cell Lines
- Tumor Cell Line
|
Below are MeSH descriptors whose meaning is more general than "Cell Line, Tumor".
Below are MeSH descriptors whose meaning is more specific than "Cell Line, Tumor".
This graph shows the total number of publications written about "Cell Line, Tumor" by people in this website by year, and whether "Cell Line, Tumor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 21 | 21 |
| 2004 | 0 | 69 | 69 |
| 2005 | 0 | 70 | 70 |
| 2006 | 1 | 62 | 63 |
| 2007 | 0 | 71 | 71 |
| 2008 | 1 | 84 | 85 |
| 2009 | 2 | 114 | 116 |
| 2010 | 0 | 97 | 97 |
| 2011 | 1 | 121 | 122 |
| 2012 | 2 | 99 | 101 |
| 2013 | 2 | 117 | 119 |
| 2014 | 0 | 146 | 146 |
| 2015 | 0 | 145 | 145 |
| 2016 | 0 | 159 | 159 |
| 2017 | 0 | 122 | 122 |
| 2018 | 0 | 148 | 148 |
| 2019 | 1 | 134 | 135 |
| 2020 | 0 | 125 | 125 |
| 2021 | 0 | 113 | 113 |
| 2022 | 0 | 44 | 44 |
| 2023 | 0 | 57 | 57 |
| 2024 | 0 | 103 | 103 |
| 2025 | 0 | 93 | 93 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cell Line, Tumor" by people in Profiles.
-
Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms in blastic phase. Blood Adv. 2025 Nov 11; 9(21):5598-5609.
-
Mutant p53 variants differentially impact replication initiation and activate cGAS-STING to affect immune checkpoint inhibition. Commun Biol. 2025 Nov 05; 8(1):1522.
-
Tunneling CARs: Increasing CAR T-Cell Tumor Infiltration through the Overexpression of MMP-7 and Osteopontin-b. Cancer Immunol Res. 2025 Nov 03; 13(11):1732-1748.
-
Integrative Proteogenomics and Forward Genetics Reveal a Novel Mitotic Vulnerability in Triple-Negative Breast Cancer. Cancer Discov. 2025 Nov 03; 15(11):2326-2343.
-
Endoglin-Directed CAR T Cells Comprehensively Target Tumors in Advanced Sarcomas. Cancer Immunol Res. 2025 Oct 01; 13(10):1591-1608.
-
TIGIT Affects CAR NK-cell Effector Function in the Solid Tumor Microenvironment by Modulating Immune Synapse Strength. Cancer Immunol Res. 2025 Oct 01; 13(10):1576-1590.
-
Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2025 Oct 01; 31(19):4184-4195.
-
Fructose and glucose from sugary drinks enhance colorectal cancer metastasis via SORD. Nat Metab. 2025 Oct; 7(10):2018-2032.
-
Synthesis, Structure-Activity Relationships, and Antitumor Activities of Quinoxiline-Containing Inhibitors of the Protein-Protein Interactions between Transcription Coactivator AF9/ENL and DOT1L/AF4. J Med Chem. 2025 Sep 25; 68(18):19396-19414.
-
Rationalized combinatorial targeting of immune co-receptors leads to tumor regression. Cytokine. 2025 Dec; 196:157030.